HEPION PHARMACEUTICALS, INC. Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
HEPION PHARMACEUTICALS, INC. (HEPA) had Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net of $225.00 thousand as of 2019-09-30, per its 10-Q filed 2019-11-14.
Discontinued › Notes › Debt › Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet · last filed 2019-11-14
- 2019-09-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $225.00K.
- 2018-09-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $225.00K.
- 2018-06-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $225.00K.
- 2018-05-09: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $225.00K.
| Period end | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net |
|---|---|
| 2019-09-30 | $225.00K 10-Q · filed 2019-11-14 |
| 2018-09-30 | $225.00K 10-Q · filed 2018-11-14 |
| 2018-06-30 | $225.00K 10-Q · filed 2018-08-14 |
| 2018-05-09 | $225.00K 10-K · filed 2019-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |